|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Plexxikon Inc.
| | | Phone: | (510) 647-4000 | Fax: | (510) 548-8014 | Year Established: | 2000 | Main Contact: | Paul Lin, MD, MBA, COO | | Other Contacts: | Joseph Young, M.B.A., VP, Finance & Corporate Development Sandra E. Tong, M.D., VP, Clinical Research Gideon E. Bollag, Ph.D., CEO Henry Hsu, M.D., CMO Chao Zhang, Ph.D., Senior VP, Research
| | Company Description | Plexxikon, a member of the Daiichi Sankyo Group since April 2011, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s drug Zelboraf® (vemurafenib/PLX4032) was approved by the FDA in 2011, and is being co-promoted in the U.S. by Daiichi Sankyo Inc. and Genentech. Plexxikon is developing a portfolio of preclinical and clinical stage compounds to address significant unmet medical needs in oncology and other therapeutic areas. Plexxikon’s Scaffold-Based Drug DiscoveryTM platform integrates multiple state-of-the-art technologies, including structural screening as a key component that provides a significant advantage over other drug discovery approaches. | |
|
|
|
|
|